1
|
Mounsey K, Harvey RJ, Wilkinson V, Takano K, Old J, Stannard H, Wicker L, Phalen D, Carver S. Drug dose and animal welfare: important considerations in the treatment of wildlife. Parasitol Res 2022; 121:1065-1071. [PMID: 35147771 PMCID: PMC8832083 DOI: 10.1007/s00436-022-07460-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Accepted: 02/01/2022] [Indexed: 10/25/2022]
Abstract
A recent publication in Parasitology Research by (Old et al. Parasitol Res 120:1077-1090, 2021) raises the topical and often controversial issue of the treatment of wildlife by personnel with little or no formal scientific training (e.g. wildlife carers). In a valuable contribution to the subject, Old and colleagues document a wide range of topical (pour-on) application doses and frequencies of moxidectin (Cydectin®) administered in situ to bare-nosed wombats (Vombatus ursinus) by members of the wildlife carer/treater community in southeast Australia to treat sarcoptic mange disease. This treatment occurred under minor use permits issued by the Australian Pesticides and Veterinary Management Authority (APVMA). These permits do not require veterinary supervision, although carers are registered and are expected to comply with the guidelines of this permit.The prevalence and severity of sarcoptic mange in wildlife is influenced by a variety of factors including mite biology, environmental conditions, population density, animal behaviour and immune susceptibility (Browne et al. Bioscience, 2021). In bare-nosed wombats, combinations of these elements play a substantial role in making the treatment of an already difficult disease more complex. (Moroni et al. Parasit Vectors 13:471, 2020) comment that any pharmacological treatment of free-ranging wildlife must consider these factors when assessing their feasibility and implications, especially in the context of emerging drug resistance and potential long-term ecological impacts. As individuals with significant interest in sarcoptic mange and representing a range of professional research and veterinary expertise, we see value in providing expert commentary on this issue.
Collapse
Affiliation(s)
- Kate Mounsey
- School of Health and Behavioural Sciences, University of the Sunshine Coast, Maroochydore, QLD, 4558, Australia. .,Sunshine Coast Health Institute, Birtinya, QLD, 4556, Australia.
| | - Robert J Harvey
- School of Health and Behavioural Sciences, University of the Sunshine Coast, Maroochydore, QLD, 4558, Australia.,Sunshine Coast Health Institute, Birtinya, QLD, 4556, Australia
| | - Victoria Wilkinson
- School of Natural Sciences, University of Tasmania, Hobart, TAS, 7005, Australia
| | - Kotaro Takano
- School of Health and Behavioural Sciences, University of the Sunshine Coast, Maroochydore, QLD, 4558, Australia.,Sunshine Coast Health Institute, Birtinya, QLD, 4556, Australia
| | - Julie Old
- School of Science, Western Sydney University, Hawkesbury campus, Penrith, NSW, 2751, Australia
| | - Hayley Stannard
- School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW, 2678, Australia
| | - Leanne Wicker
- Wildlife Conservation and Science, Zoos Victoria, Parkville, VIC, 3052, Australia
| | - David Phalen
- Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Sydney, NSW, 2006, Australia
| | - Scott Carver
- School of Natural Sciences, University of Tasmania, Hobart, TAS, 7005, Australia
| |
Collapse
|
2
|
Wilkinson V, Takano K, Nichols D, Martin A, Holme R, Phalen D, Mounsey K, Charleston M, Kreiss A, Pye R, Browne E, Næsborg-Nielsen C, Richards SA, Carver S. Correction to: Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable use. Parasit Vectors 2021; 14:140. [PMID: 33673849 PMCID: PMC7934268 DOI: 10.1186/s13071-021-04658-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023] Open
Affiliation(s)
- Vicky Wilkinson
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, TAS, Australia.
| | - Kotaro Takano
- The University of the Sunshine Coast, 90 Sippy Downs Dr, Sippy Downs, QLD, Australia
| | - David Nichols
- Central Science Laboratory, University of Tasmania, Private Bag 74, Hobart, TAS, Australia
| | - Alynn Martin
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, TAS, Australia
| | - Roz Holme
- Cedar Creek Wombat Rescue Inc, PO Box 538, Cessnock, NSW, Australia
| | - David Phalen
- The University of Sydney, C01A, JI Shute, Camden, Sydney, NSW, Australia
| | - Kate Mounsey
- The University of the Sunshine Coast, 90 Sippy Downs Dr, Sippy Downs, QLD, Australia
| | - Michael Charleston
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, TAS, Australia
| | - Alexandre Kreiss
- Bonorong Wildlife Sanctuary, 593 Briggs Rd, Brighton, TAS, Australia
| | - Ruth Pye
- Bonorong Wildlife Sanctuary, 593 Briggs Rd, Brighton, TAS, Australia
| | - Elizabeth Browne
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, TAS, Australia
| | | | - Shane A Richards
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, TAS, Australia
| | - Scott Carver
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, TAS, Australia
| |
Collapse
|
3
|
Chng L, Holt DC, Field M, Francis JR, Tilakaratne D, Dekkers MH, Robinson G, Mounsey K, Pavlos R, Bowen AC, Fischer K, Papenfuss AT, Gasser RB, Korhonen PK, Currie BJ, McCarthy JS, Pasay C. Molecular diagnosis of scabies using a novel probe-based polymerase chain reaction assay targeting high-copy number repetitive sequences in the Sarcoptes scabiei genome. PLoS Negl Trop Dis 2021; 15:e0009149. [PMID: 33626043 PMCID: PMC7939366 DOI: 10.1371/journal.pntd.0009149] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 03/08/2021] [Accepted: 01/15/2021] [Indexed: 01/23/2023] Open
Abstract
Background The suboptimal sensitivity and specificity of available diagnostic methods for scabies hampers clinical management, trials of new therapies and epidemiologic studies. Additionally, parasitologic diagnosis by microscopic examination of skin scrapings requires sample collection with a sharp scalpel blade, causing discomfort to patients and difficulty in children. Polymerase chain reaction (PCR)-based diagnostic assays, combined with non-invasive sampling methods, represent an attractive approach. In this study, we aimed to develop a real-time probe-based PCR test for scabies, test a non-invasive sampling method and evaluate its diagnostic performance in two clinical settings. Methodology/Principal findings High copy-number repetitive DNA elements were identified in draft Sarcoptes scabiei genome sequences and used as assay targets for diagnostic PCR. Two suitable repetitive DNA sequences, a 375 base pair microsatellite (SSR5) and a 606 base pair long tandem repeat (SSR6), were identified. Diagnostic sensitivity and specificity were tested using relevant positive and negative control materials and compared to a published assay targeting the mitochondrial cox1 gene. Both assays were positive at a 1:100 dilution of DNA from a single mite; no amplification was observed in DNA from samples from 19 patients with other skin conditions nor from house dust, sheep or dog mites, head and body lice or from six common skin bacterial and fungal species. Moderate sensitivity of the assays was achieved in a pilot study, detecting 5/7 (71.4% [95% CI: 29.0% - 96.3%]) of clinically diagnosed untreated scabies patients). Greater sensitivity was observed in samples collected by FLOQ swabs compared to skin scrapings. Conclusions/Significance This newly developed qPCR assay, combined with the use of an alternative non-invasive swab sampling technique offers the possibility of enhanced diagnosis of scabies. Further studies will be required to better define the diagnostic performance of these tests. As scabies control efforts continue to grow, scarcity of diagnostic options hinders success of elimination efforts in endemic areas. Efficiency in large-scale monitoring is further obstructed by invasive sample collection techniques, which are often uncomfortable for patients, and lack sensitivity. We have developed two PCR-based diagnostic assays targeting repetitive DNA elements. These were identified using new data on the S. scabiei genome. Targeting these elements by PCR improved the detection of scabies DNA. Enhanced sensitivity was demonstrated when tested against routine microscopy and a published PCR-based diagnostic assay. When combined with a non-invasive, effective FLOQ swab sampling method, the developed qPCR-based assays may provide a useful complementary tool for diagnosis of scabies, and its application will likely improve scabies control in target populations.
Collapse
Affiliation(s)
- Lena Chng
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Deborah C. Holt
- Menzies School of Health Research, Charles Darwin University, Darwin, Australia
- College of Health and Human Sciences, Charles Darwin University, Darwin, Australia
| | - Matt Field
- Centre for Tropical Bioinformatics and Molecular Biology and Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia
- Genome Informatics, John Curtin School of Medical Research, Australian National University, Canberra, Australia
| | - Joshua R. Francis
- Menzies School of Health Research, Charles Darwin University, Darwin, Australia
- Royal Darwin Hospital, Tiwi, Australia
| | - Dev Tilakaratne
- Royal Darwin Hospital, Tiwi, Australia
- Darwin Dermatology, Tiwi, Australia
| | - Milou H. Dekkers
- Queensland Animal Science Precinct, University of Queensland, Gatton, Australia
| | - Greg Robinson
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Kate Mounsey
- University of Sunshine Coast, Sippy Downs, Australia
| | - Rebecca Pavlos
- Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Australia
| | - Asha C. Bowen
- Menzies School of Health Research, Charles Darwin University, Darwin, Australia
- Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Australia
- Department of Infectious Diseases, Perth Children’s Hospital, Perth, Australia
| | - Katja Fischer
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | | | - Robin B. Gasser
- Department of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Veterinary Sciences, The University of Melbourne, Parkville, Australia
| | - Pasi K. Korhonen
- Department of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Veterinary Sciences, The University of Melbourne, Parkville, Australia
| | - Bart J. Currie
- Menzies School of Health Research, Charles Darwin University, Darwin, Australia
- Royal Darwin Hospital, Tiwi, Australia
| | | | - Cielo Pasay
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
- * E-mail:
| |
Collapse
|
4
|
Wilkinson V, Takano K, Nichols D, Martin A, Holme R, Phalen D, Mounsey K, Charleston M, Kreiss A, Pye R, Browne E, Næsborg-Nielsen C, Richards SA, Carver S. Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable use. Parasit Vectors 2021; 14:18. [PMID: 33407820 PMCID: PMC7789169 DOI: 10.1186/s13071-020-04500-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Accepted: 11/23/2020] [Indexed: 12/16/2022] Open
Abstract
Background Sarcoptic mange causes significant animal welfare and occasional conservation concerns for bare-nosed wombats (Vombatus ursinus) throughout their range. To date, in situ chemotherapeutic interventions have involved macrocytic lactones, but their short duration of action and need for frequent re-administration has limited treatment success. Fluralaner (Bravecto®; MSD Animal Health), a novel isoxazoline class ectoparasiticide, has several advantageous properties that may overcome such limitations. Methods Fluralaner was administered topically at 25 mg/kg (n = 5) and 85 mg/kg (n = 2) to healthy captive bare-nosed wombats. Safety was assessed over 12 weeks by clinical observation and monitoring of haematological and biochemical parameters. Fluralaner plasma pharmacokinetics were quantified using ultra-performance liquid chromatography and tandem mass spectrometry. Efficacy was evaluated through clinical assessment of response to treatment, including mange and body condition scoring, for 15 weeks after topical administration of 25 mg/kg fluralaner to sarcoptic mange-affected wild bare-nosed wombats (n = 3). Duration of action was determined through analysis of pharmacokinetic parameters and visual inspection of study subjects for ticks during the monitoring period. Methods for diluting fluralaner to enable ‘pour-on’ application were compared, and an economic and treatment effort analysis of fluralaner relative to moxidectin was undertaken. Results No deleterious health impacts were detected following fluralaner administration. Fluralaner was absorbed and remained quantifiable in plasma throughout the monitoring period. For the 25 mg/kg and 85 mg/kg treatment groups, the respective means for maximum recorded plasma concentrations (Cmax) were 6.2 and 16.4 ng/ml; for maximum recorded times to Cmax, 3.0 and 37.5 days; and for plasma elimination half-lives, 40.1 and 166.5 days. Clinical resolution of sarcoptic mange was observed in all study animals within 3–4 weeks of treatment, and all wombats remained tick-free for 15 weeks. A suitable product for diluting fluralaner into a ‘pour-on’ was found. Treatment costs were competitive, and predicted treatment effort was substantially lower relative to moxidectin. Conclusions Fluralaner appears to be a safe and efficacious treatment for sarcoptic mange in the bare-nosed wombat, with a single dose lasting over 1–3 months. It has economic and treatment-effort-related advantages over moxidectin, the most commonly used alternative. We recommend a dose of 25 mg/kg fluralaner and, based on the conservative assumption that at least 50% of a dose makes dermal contact, Bravecto Spot-On for Large Dogs as the most appropriate formulation for adult bare-nosed wombats. Graphical abstract ![]()
Collapse
Affiliation(s)
- Vicky Wilkinson
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia.
| | - Kotaro Takano
- The University of the Sunshine Coast, 90 Sippy Downs Dr, Sippy Downs, QLD, Australia
| | - David Nichols
- Central Science Laboratory, University of Tasmania, Private Bag 74, Hobart, Tasmania, Australia
| | - Alynn Martin
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia
| | - Roz Holme
- Cedar Creek Wombat Rescue Inc, PO Box 538, Cessnock, NSW, Australia
| | - David Phalen
- The University of Sydney, C01A, JI Shute, Camden, Sydney, NSW, Australia
| | - Kate Mounsey
- The University of the Sunshine Coast, 90 Sippy Downs Dr, Sippy Downs, QLD, Australia
| | - Michael Charleston
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia
| | - Alexandre Kreiss
- Bonorong Wildlife Sanctuary, 593 Briggs Rd, Brighton, Tasmania, Australia
| | - Ruth Pye
- Bonorong Wildlife Sanctuary, 593 Briggs Rd, Brighton, Tasmania, Australia
| | - Elizabeth Browne
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia
| | | | - Shane A Richards
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia
| | - Scott Carver
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia
| |
Collapse
|
5
|
Fraser TA, Carver S, Martin AM, Mounsey K, Polkinghorne A, Jelocnik M. A Sarcoptes scabiei specific isothermal amplification assay for detection of this important ectoparasite of wombats and other animals. PeerJ 2018; 6:e5291. [PMID: 30065882 PMCID: PMC6065476 DOI: 10.7717/peerj.5291] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Accepted: 07/02/2018] [Indexed: 11/20/2022] Open
Abstract
Background The globally distributed epidermal ectoparasite, Sarcoptes scabiei, is a serious health and welfare burden to at-risk human and animal populations. Rapid and sensitive detection of S. scabiei infestation is critical for intervention strategies. While direct microscopy of skin scrapings is a widely utilised diagnostic method, it has low sensitivity. PCR, alternatively, has been shown to readily detect mite DNA even in microscopy-negative skin scrapings. However, a limitation to the latter method is the requirements for specialised equipment and reagents. Such resources may not be readily available in regional or remote clinical settings and are an important consideration in diagnosis of this parasitic disease. Methodology A Loop Mediated Isothermal Amplification (LAMP) assay targeting the ITS-2 gene for S. scabiei was developed and evaluated on clinical samples from various hosts, previously screened with conventional S. scabies-specific PCR. Species specificity of the newly developed LAMP assay was tested against a range of DNA samples from other arthropods. The LAMP assays were performed on a real-time fluorometer as well as thermal cycler to evaluate an end-point of detection. Using skin scrapings, a rapid sample processing method was assessed to eliminate extensive processing times involved with DNA extractions prior to diagnostic assays, including LAMP. Results The S. scabiei LAMP assay was demonstrated to be species-specific and able to detect DNA extracted from a single mite within a skin scraping in under 30 minutes. Application of this assay to DNA extracts from skin scrapings taken from a range of hosts revealed 92.3% congruence (with 92.50% specificity and 100% sensitivity) to the conventional PCR detection of S. scabiei. Preliminary results have indicated that diagnostic outcome from rapidly processed dry skin scrapings using our newly developed LAMP is possible in approximately 40 minutes. Discussion We have developed a novel, rapid and robust molecular assay for detecting S. scabiei infesting humans and animals. Based on these findings, we anticipate that this assay will serve an important role as an ancillary diagnostic tool at the point-of-care, complementing existing diagnostic protocols for S. scabiei.
Collapse
Affiliation(s)
- Tamieka A Fraser
- USC Animal Research Centre, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Sippy Downs, Australia.,Department of Biological Sciences, University of Tasmania, Sandy Bay, Australia
| | - Scott Carver
- Department of Biological Sciences, University of Tasmania, Sandy Bay, Australia
| | - Alynn M Martin
- Department of Biological Sciences, University of Tasmania, Sandy Bay, Australia
| | - Kate Mounsey
- USC Animal Research Centre, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Sippy Downs, Australia.,School of Health and Sport Sciences, University of the Sunshine Coast, Sippy Downs, Australia
| | - Adam Polkinghorne
- USC Animal Research Centre, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Sippy Downs, Australia
| | - Martina Jelocnik
- USC Animal Research Centre, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Sippy Downs, Australia
| |
Collapse
|
6
|
Abstract
Genital warts are one of the most common sexually transmitted diseases worldwide. The disease is a result of infection with low-risk types of human papillomaviruses, mostly type 6 and 11. Current therapies for genital warts are mainly ablative, or alternatively topical application of imiquimod cream and sinecatechin (polyphenon E) ointment to the warts. However, low patient compliance and high recurrence rate are significant problems for the treatment of genital warts by imiquimod and ablative therapies. We summarise recent literature in this area and propose combining imiquimod with other therapies to increase the efficacy of imiquimod.
Collapse
Affiliation(s)
- Jianwei Yuan
- a Institute of Molecular Diagnosis and Target Therapy, First Affiliated Hospital , Guangdong Pharmaceutical University , Guangzhou , Guangdong , China
| | - Guoying Ni
- c Inflammation and Healing research cluster, Faculty of Science, Health , Education and Engineering, University of the Sunshine Coast , Maroochydore DC , Australia
| | - Tianfang Wang
- b Genecology Research Centre, Faculty of Science, Health, Education and Engineering , University of the Sunshine Coast , Maroochydore DC , Australia
| | - Kate Mounsey
- c Inflammation and Healing research cluster, Faculty of Science, Health , Education and Engineering, University of the Sunshine Coast , Maroochydore DC , Australia
| | - Shelley Cavezza
- c Inflammation and Healing research cluster, Faculty of Science, Health , Education and Engineering, University of the Sunshine Coast , Maroochydore DC , Australia
| | - Xuan Pan
- a Institute of Molecular Diagnosis and Target Therapy, First Affiliated Hospital , Guangdong Pharmaceutical University , Guangzhou , Guangdong , China
| | - Xiaosong Liu
- a Institute of Molecular Diagnosis and Target Therapy, First Affiliated Hospital , Guangdong Pharmaceutical University , Guangzhou , Guangdong , China.,c Inflammation and Healing research cluster, Faculty of Science, Health , Education and Engineering, University of the Sunshine Coast , Maroochydore DC , Australia
| |
Collapse
|
7
|
Ni G, Liao Z, Chen S, Wang T, Yuan J, Pan X, Mounsey K, Cavezza S, Liu X, Wei MQ. Blocking IL-10 signalling at the time of immunization does not increase unwanted side effects in mice. BMC Immunol 2017; 18:40. [PMID: 28810829 PMCID: PMC5557397 DOI: 10.1186/s12865-017-0224-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2016] [Accepted: 08/01/2017] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Cancer therapeutic vaccine induced cytotoxic T cell (CTL) responses are pivotal for the killing of tumour cells. Blocking interleukin 10 (IL-10) signalling at the time of immunization increases vaccine induced CTL responses and improves prevention of tumour growth in animal models compared to immunization without an IL-10 signalling blockade. Therefore, this immunization strategy may have potential to curtail cancer in a clinical setting. However, IL-10 deficiency leads to autoimmune disease in the gut. Blocking IL-10 at the time of immunization may result in unwanted side effects, especially immune-pathological diseases in the intestine. METHODS We investigated whether blocking IL-10 at the time of immunization results in intestinal inflammation responses in a mouse TC-1 tumour model and in a NOD autoimmune disease prone mouse model. RESULTS We now show that blocking IL-10 at the time of immunization increases IL-10 production by CD4+ T cells in the spleen and draining lymph nodes, and does not result in blood cell infiltration to the intestines leading to intestinal pathological changes. Moreover, immunization with papillomavirus like particles combined with simultaneously blocking IL-10 signalling does not increase the incidence of autoimmune disease in Non-obese diabetic (NOD) mice. CONCLUSIONS Our results indicate that immunization with an IL-10 inhibitor may facilitate the generation of safe, effective therapeutic vaccines against chronic viral infection and cancer.
Collapse
Affiliation(s)
- Guoying Ni
- School of Medical Science, Griffith Health Institute, Griffith University, Gold Coast, QLD 4333 Australia
| | - Zaowen Liao
- Cancer Research Institute, The First People’s Hospital of Foshan, Foshan, Guangdong 528000 China
| | - Shu Chen
- Cancer Research Institute, The First People’s Hospital of Foshan, Foshan, Guangdong 528000 China
| | - Tianfang Wang
- Inflammation and Healing Research Cluster, University of the Sunshine Coast, Maroochydore DC, QLD 4558 Australia
| | - Jianwei Yuan
- Molecular diagnosis and Target Therapy Laboratory, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong China
| | - Xuan Pan
- Molecular diagnosis and Target Therapy Laboratory, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong China
| | - Kate Mounsey
- Inflammation and Healing Research Cluster, University of the Sunshine Coast, Maroochydore DC, QLD 4558 Australia
| | - Shelley Cavezza
- Inflammation and Healing Research Cluster, University of the Sunshine Coast, Maroochydore DC, QLD 4558 Australia
| | - Xiaosong Liu
- Cancer Research Institute, The First People’s Hospital of Foshan, Foshan, Guangdong 528000 China
- Inflammation and Healing Research Cluster, University of the Sunshine Coast, Maroochydore DC, QLD 4558 Australia
- Molecular diagnosis and Target Therapy Laboratory, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong China
| | - Ming Q. Wei
- School of Medical Science, Griffith Health Institute, Griffith University, Gold Coast, QLD 4333 Australia
| |
Collapse
|
8
|
Ni G, Wang Y, Cummins S, Walton S, Mounsey K, Liu X, Wei MQ, Wang T. Inhibitory mechanism of peptides with a repeating hydrophobic and hydrophilic residue pattern on interleukin-10. Hum Vaccin Immunother 2016; 13:518-527. [PMID: 27686406 DOI: 10.1080/21645515.2016.1238537] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
Interleukin 10 (IL-10) is a cytokine that is able to downregulate inflammation. Its overexpression is directly associated with the difficulty in the clearance of chronic viral infections, such as chronic hepatitis B, hepatitis C and HIV infection, and infection-related cancer. IL-10 signaling blockade has been proposed as a promising way of clearing chronic viral infection and preventing tumor growth in animal models. Recently, we have reported that peptides with a helical repeating pattern of hydrophobic and hydrophilic residues are able to inhibit IL-10 significantly both in vitro and in vivo. 1 In this work, we seek to further study the inhibiting mechanism of these peptides using sequence-modified peptides. As evidenced by both experimental and molecular dynamics simulation in concert the N-terminal hydrophobic peptide constructed with repeating hydrophobic and hydrophilic pattern of residues is more likely to inhibit IL10. In addition, the sequence length and the ability of protonation are also important for inhibition activity.
Collapse
Affiliation(s)
- Guoying Ni
- a Genecology Research Centre , University of the Sunshine Coast , Maroochydore , DC , Australia.,b School of Medical Science, Griffith Health Institute , Griffith University , Gold Coast , Australia
| | - Yuejian Wang
- c Cancer Research Institute, Foshan First People's Hospital , Foshan , Guangdong , China
| | - Scott Cummins
- a Genecology Research Centre , University of the Sunshine Coast , Maroochydore , DC , Australia
| | - Shelley Walton
- d Inflammation and Healing Research Cluster, School of Health and Sport Sciences , University of Sunshine Coast , Maroochydore , DC , Australia
| | - Kate Mounsey
- d Inflammation and Healing Research Cluster, School of Health and Sport Sciences , University of Sunshine Coast , Maroochydore , DC , Australia
| | - Xiaosong Liu
- c Cancer Research Institute, Foshan First People's Hospital , Foshan , Guangdong , China.,d Inflammation and Healing Research Cluster, School of Health and Sport Sciences , University of Sunshine Coast , Maroochydore , DC , Australia
| | - Ming Q Wei
- b School of Medical Science, Griffith Health Institute , Griffith University , Gold Coast , Australia
| | - Tianfang Wang
- a Genecology Research Centre , University of the Sunshine Coast , Maroochydore , DC , Australia
| |
Collapse
|
9
|
Mounsey K, Kearns T, Rampton M, Llewellyn S, King M, Holt D, Currie BJ, Andrews R, Nutman T, McCarthy J. Use of dried blood spots to define antibody response to the Strongyloides stercoralis recombinant antigen NIE. Acta Trop 2014; 138:78-82. [PMID: 25051188 DOI: 10.1016/j.actatropica.2014.07.007] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2013] [Revised: 07/08/2014] [Accepted: 07/11/2014] [Indexed: 11/29/2022]
Abstract
An approach to improve the diagnosis of Strongyloides stercoralis infection is the use of serologic assays utilising the NIE antigen from S. stercoralis, with good diagnostic sensitivity and excellent specificity reported. Detection of antibody eluted from dried blood spots (DBS) has shown utility in large-scale seroepidemiological studies for a range of conditions and is appealing for use with children where sample collection is difficult. We adapted an existing NIE-enzyme linked immunosorbent assay (ELISA) for the testing of strongyloides antibody response on DBS, and evaluated it in a population screening and mass drug administration programme (MDA) for strongyloidiasis conducted in an Australian indigenous community. Study participants were treated with 200 μg/kg ivermectin (>15 kg) or 3× 400 mg albendazole (<15kg). The sensitivity of the NIE DBS-ELISA was determined by receiver operator characteristic (ROC) analysis to be 85.7%. A total of 214 DBS were collected from 184 participants across two screening and MDA encounters. A total of 27 of 164 participants (16.5%) tested positive for S. stercoralis NIE-DBS prior to MDA treatment, and 6 of 50 participants (12.0%) tested positive after treatment. These prevalence values are similar to those documented by standard serology in the same community. For 30 participants where a DBS was collected at both MDA 1 and 2, a significant decline in ELISA values was evident post treatment (0.12-0.02, p=0.0012). These results are in agreement with previous studies documenting the high seroprevalence of S. stercoralis in remote Australian Indigenous communities, and suggest that collection of dried blood spots may be a useful approach for field diagnosis of S. stercoralis seroprevalence.
Collapse
Affiliation(s)
- Kate Mounsey
- School of Health & Sport Sciences, University of the Sunshine Coast, Locked Bag 4, Maroochydore, QLD 4558, Australia; QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, Australia.
| | - Therese Kearns
- Menzies School of Health Research, Charles Darwin University, Casuarina, NT, Australia.
| | - Melanie Rampton
- QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, Australia.
| | - Stacey Llewellyn
- QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, Australia.
| | - Mallory King
- QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, Australia.
| | - Deborah Holt
- Menzies School of Health Research, Charles Darwin University, Casuarina, NT, Australia.
| | - Bart J Currie
- Menzies School of Health Research, Charles Darwin University, Casuarina, NT, Australia.
| | - Ross Andrews
- Menzies School of Health Research, Charles Darwin University, Casuarina, NT, Australia.
| | - Thomas Nutman
- National Institutes of Health, Bethesda, MD, United States.
| | - James McCarthy
- QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, Australia; School of Medicine, University of Queensland, Herston, QLD, Australia.
| |
Collapse
|
10
|
Pasay C, Rothwell J, Mounsey K, Kelly A, Hutchinson B, Miezler A, McCarthy J. An exploratory study to assess the activity of the acarine growth inhibitor, fluazuron, against Sarcoptes scabei infestation in pigs. Parasit Vectors 2012; 5:40. [PMID: 22336283 PMCID: PMC3298804 DOI: 10.1186/1756-3305-5-40] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2011] [Accepted: 02/16/2012] [Indexed: 11/21/2022] Open
Abstract
Background The most common treatments for scabies in human and veterinary settings are topical 5% permethrin or systemic treatment with ivermectin. However, these treatments have very little activity against arthropod eggs, and therefore repeated treatment is frequently required. In-vitro, biochemical and molecular studies have demonstrated that human mites are becoming increasingly resistant to both acaricides. To identify alternate acaricides, we undertook a pilot study of the in vivo activity of the benzoylphenyl urea inhibitor of chitin synthesis, fluazuron, in pigs with sarcoptic mange. Findings Pigs (n = 5) were infested with S. scabei var suis, and randomised to treatment at the start of peak infestation with fluazuron at a dose of 10 mg/kg/day per os for 7 days (n = 3) or no treatment (n = 2). Clinical scores, skin scrapings for mite counts and blood sampling for pharmacokinetic analysis were undertaken. Fluazuron was well absorbed in treated pigs with measureable blood levels up to 4 weeks post treatment. No adverse effects were observed. Modest acaricidal activity of the compound was observed, with a reduction in severity of skin lesions in treated pigs, as well as a reduction in number of scabies mite's early life stages. Conclusions The moderate efficacy of fluazuron against scabies mites indicates a lead to the development of alternate treatments for scabies, such as combination therapies that maybe applicable for human use in the future.
Collapse
Affiliation(s)
- Cielo Pasay
- Clinical Tropical Medicine Laboratory, Queensland Institute of Medical Research, Herston, Australia.
| | | | | | | | | | | | | |
Collapse
|
11
|
Pasay C, Mounsey K, Stevenson G, Davis R, Arlian L, Morgan M, Vyszenski-Moher D, Andrews K, McCarthy J. Acaricidal activity of eugenol based compounds against scabies mites. PLoS One 2010; 5:e12079. [PMID: 20711455 PMCID: PMC2920318 DOI: 10.1371/journal.pone.0012079] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2010] [Accepted: 07/14/2010] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Human scabies is a debilitating skin disease caused by the "itch mite" Sarcoptes scabiei. Ordinary scabies is commonly treated with topical creams such as permethrin, while crusted scabies is treated with topical creams in combination with oral ivermectin. Recent reports of acaricide tolerance in scabies endemic communities in Northern Australia have prompted efforts to better understand resistance mechanisms and to identify potential new acaricides. In this study, we screened three essential oils and four pure compounds based on eugenol for acaricidal properties. METHODOLOGY/PRINCIPAL FINDINGS Contact bioassays were performed using live permethrin-sensitive S. scabiei var suis mites harvested from pigs and permethrin-resistant S. scabiei var canis mites harvested from rabbits. Results of bioassays showed that clove oil was highly toxic against scabies mites. Nutmeg oil had moderate toxicity and ylang ylang oil was the least toxic. Eugenol, a major component of clove oil and its analogues--acetyleugenol and isoeugenol, demonstrated levels of toxicity comparable to benzyl benzoate, the positive control acaricide, killing mites within an hour of contact. CONCLUSIONS The acaricidal properties demonstrated by eugenol and its analogues show promise as leads for future development of alternative topical acaricides to treat scabies.
Collapse
Affiliation(s)
- Cielo Pasay
- Queensland Institute of Medical Research and Australian Centre for International and Tropical Health, University of Queensland, Brisbane, Queensland, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Mounsey K, Ho MF, Kelly A, Willis C, Pasay C, Kemp DJ, McCarthy JS, Fischer K. A tractable experimental model for study of human and animal scabies. PLoS Negl Trop Dis 2010; 4:e756. [PMID: 20668508 PMCID: PMC2907415 DOI: 10.1371/journal.pntd.0000756] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2010] [Accepted: 06/04/2010] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Scabies is a parasitic skin infestation caused by the burrowing mite Sarcoptes scabiei. It is common worldwide and spreads rapidly under crowded conditions, such as those found in socially disadvantaged communities of Indigenous populations and in developing countries. Pruritic scabies lesions facilitate opportunistic bacterial infections, particularly Group A streptococci. Streptococcal infections cause significant sequelae and the increased community streptococcal burden has led to extreme levels of acute rheumatic fever and rheumatic heart disease in Australia's Indigenous communities. In addition, emerging resistance to currently available therapeutics emphasizes the need to identify potential targets for novel chemotherapeutic and/or immunological intervention. Scabies research has been severely limited by the availability of parasites, and scabies remains a truly neglected infectious disease. We report development of a tractable model for scabies in the pig, Sus domestica. METHODOLOGY/PRINCIPAL FINDINGS Over five years and involving ten independent cohorts, we have developed a protocol for continuous passage of Sarcoptes scabiei var. suis. To increase intensity and duration of infestation without generating animal welfare issues we have optimised an immunosuppression regimen utilising daily oral treatment with 0.2 mg/kg dexamethasone. Only mild, controlled side effects are observed, and mange infection can be maintained indefinitely providing large mite numbers (> 6000 mites/g skin) for molecular-based research on scabies. In pilot experiments we explore whether any adaptation of the mite population is reflected in genetic changes. Phylogenetic analysis was performed comparing sets of genetic data obtained from pig mites collected from naturally infected pigs with data from pig mites collected from the most recent cohort. CONCLUSIONS/SIGNIFICANCE A reliable pig/scabies animal model will facilitate in vivo studies on host immune responses to scabies including the relations to the associated bacterial pathogenesis and more detailed studies of molecular evolution and host adaptation. It is a most needed tool for the further investigation of this important and widespread parasitic disease.
Collapse
Affiliation(s)
- Kate Mounsey
- Queensland Institute of Medical Research and Australian Centre for International and Tropical Health and Nutrition, University of Queensland, Brisbane, Queensland, Australia
- Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia
| | - Mei-Fong Ho
- Queensland Institute of Medical Research and Australian Centre for International and Tropical Health and Nutrition, University of Queensland, Brisbane, Queensland, Australia
| | - Andrew Kelly
- Department of Employment, Economic Development and Innovation, Centre for Advanced Animal Science, University of Queensland, Gatton, Queensland, Australia
| | - Charlene Willis
- Queensland Institute of Medical Research and Australian Centre for International and Tropical Health and Nutrition, University of Queensland, Brisbane, Queensland, Australia
- Griffith Medical Research College, a joint program of Griffith University and the Queensland Institute of Medical Research, QIMR, Herston, Queensland, Australia
| | - Cielo Pasay
- Queensland Institute of Medical Research and Australian Centre for International and Tropical Health and Nutrition, University of Queensland, Brisbane, Queensland, Australia
| | - David J. Kemp
- Queensland Institute of Medical Research and Australian Centre for International and Tropical Health and Nutrition, University of Queensland, Brisbane, Queensland, Australia
| | - James S. McCarthy
- Queensland Institute of Medical Research and Australian Centre for International and Tropical Health and Nutrition, University of Queensland, Brisbane, Queensland, Australia
| | - Katja Fischer
- Queensland Institute of Medical Research and Australian Centre for International and Tropical Health and Nutrition, University of Queensland, Brisbane, Queensland, Australia
- * E-mail:
| |
Collapse
|